Guides
6 pages in this section, most recently updated September 4, 2026.
- 01
Methodology and the A to D grading scale
How this site grades peptide evidence: four letters for the kind of human evidence that exists, one flag for a published FDA safety concern, and the rules for what counts, what does not, and why a negative trial and a positive one can share a letter.
Updated September 4, 2026
- 02
The FDA 503A bulks list, explained for peptide buyers
What section 503A allows a pharmacy to compound from, what the bulks list and its three interim categories are, what happened to peptides on September 29, 2023 and since, and what 'nominated but withdrawn' and a PCAC discussion actually mean for the product in front of you.
Updated September 4, 2026
- 03
How to read a peptide study in ten minutes
Six questions to ask of any study a peptide seller cites: which molecule, which species, what control, what endpoint, who ran it, and has anyone repeated it. Worked examples from TB-500, epitalon, MOTS-c and the tesamorelin label.
Updated September 4, 2026
- 04
Why peptide 'stacks' fail evidence standards, and why this site publishes no doses
A stack multiplies unknowns. Each component has at best one small trial; the combination has none; the doses come from forums; the product is a research chemical. This page sets out why combination claims cannot be evaluated, and why pairing dosing content with reconstitution instructions is the line FDA draws for unapproved drugs.
Updated September 4, 2026
- 05
Storage and handling of prescribed peptide medication, per label
What the Egrifta SV, Egrifta WR and Vyleesi labels say about temperature, light, reconstitution, and when to discard, side by side. For medication a prescriber prescribed and a pharmacy dispensed. With a note on why a compounded product's label, not these, governs a compounded product.
Updated September 4, 2026
- 06
Glossary: the terms on this site, defined
Plain definitions of the regulatory and research terms used across the Peptide Reference: 503A and 503B, bulks list, Category 1 to 3, PCAC, beyond-use date, immunogenicity, RCT, primary endpoint, research use only, and more, each with the page where it matters.
Updated September 4, 2026